Drug class
Phosphate Binder Agents
Phosphate binder agents are a therapeutic class of medications used to control serum phosphorus levels in patients with hyperphosphatemia. Read more about Phosphate Binder Agents
70 drugs in this class 46 manufacturers
Drugs in Phosphate Binder Agents
SEVELAMER CARBONATE
SEVELAMER HCL
SEVELAMER CARBONATE
CALCIUM ACETATE
CALCIUM ACETATE
CALCIUM ACETATE
SEVELAMER CARBONATE
SEVELAMER CARBONATE
Phosphate binder agents are a therapeutic class of medications used to control serum phosphorus levels in patients with hyperphosphatemia.
These agents work primarily within the gastrointestinal tract by binding dietary phosphate to form insoluble complexes, which prevents systemic absorption and promotes elimination through the feces.
The class encompasses calcium-based binders, non-calcium polymers such as sevelamer, lanthanum carbonate, and iron-based formulations.
They are principally indicated for the management of hyperphosphatemia in individuals with advanced chronic kidney disease, particularly those undergoing hemodialysis or peritoneal dialysis, to prevent complications such as secondary hyperparathyroidism, vascular calcification, and renal osteodystrophy.
-
fda.gov
Phosphate binder agents are a therapeutic class of medications used to control serum phosphorus levels in patients with hyperphosphatemia The class encompasses calcium-based binders, non-calcium polymers such as sevelamer, lanthanum carbonate, and iron-based formulations They are principally indicated for the management of hyperphosphatemia in individuals with advanced chronic kidney disease, particularly those undergoing hemodialysis or peritoneal dialysis, to prevent complications such as seco...
-
fda.gov
Phosphate binder agents are a therapeutic class of medications used to control serum phosphorus levels in patients with hyperphosphatemia These agents work primarily within the gastrointestinal tract by binding dietary phosphate to form insoluble complexes, which prevents systemic absorption and promotes elimination through the feces
-
fda.gov
These agents work primarily within the gastrointestinal tract by binding dietary phosphate to form insoluble complexes, which prevents systemic absorption and promotes elimination through the feces
-
fda.gov
They are principally indicated for the management of hyperphosphatemia in individuals with advanced chronic kidney disease, particularly those undergoing hemodialysis or peritoneal dialysis, to prevent complications such as secondary hyperparathyroidism, vascular calcification, and renal osteodystrophy
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.